Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
Schrock, Alexa B., Zhu, Viola W., Hsieh, Wen-Son, Madison, Russell, Creelan, Benjamin, Silberberg, Jeffrey, Costin, Dan, Bharne, Anjali, Bonta, Ioana, Bosemani, Thangavijayan, Nikolinakos, Petros, RosLanguage:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.05.027
Date:
June, 2018
File:
PDF, 792 KB
english, 2018